Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Trading Plan

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on January 31, 2025 and February 3, 2025 under a pre-arranged 10b5-1 trading plan.

Summary

• Songjiang Ma, President of Gyre Therapeutics, sold 2,000 shares of common stock on January 31, 2025, at a weighted average price of $11.51 per share.
• Another 2,000 shares were sold on February 3, 2025, at a weighted average price of $11.47 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
• Following these transactions, Ma indirectly owns 2,887,138 shares through his spouse.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports stock sales under a pre-existing trading plan. There's no indication of positive or negative implications for the company.

Industry Context

Sales by company presidents are common and can be for a variety of reasons, including diversification, tax planning, or personal liquidity needs. The use of a 10b5-1 trading plan allows insiders to sell shares without being accused of trading on inside information.

Stakeholder Impact

• The stock sales could have a minor negative impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates